Blitzer A, Brin M F
Department of Otolaryngology, Columbia-Presbyterian Medical Center, New York, New York 10032.
Ann Otol Rhinol Laryngol. 1991 Feb;100(2):85-9. doi: 10.1177/000348949110000201.
Laryngeal dystonia is a syndrome characterized by action-induced, involuntary spasms of the laryngeal muscles. Most patients have involvement of the adductor laryngeal muscles producing uncontrolled spasms during phonation, and a "strain-strangle" speech pattern commonly termed "spastic dysphonia." Other patients have involvement of the abductor muscles producing "whispering dysphonia." Rare patients have paradoxical vocal cord motion during respiration with adductor spasms on inspiration. Over the past 5 years we have used botulinum toxin (BOTOX) to treat more than 200 patients with laryngeal dystonia. This group includes patients with adductor involvement (phonatory dystonia, recurrent laryngeal nerve section failure, respiratory dystonia) and those with abductor involvement (whispering dystonia). Patients received benefit within 24 to 72 hours, with sustained improvement for 2 to 9 months with an average of 4 months. Patients improved to an average of 90% of normal function. Clinically significant adverse effects included extended breathy dysphonia and mild choking on fluids. BOTOX has become our treatment of choice for dystonic conditions of the larynx.
喉肌张力障碍是一种以动作诱发的喉部肌肉不自主痉挛为特征的综合征。大多数患者的喉内收肌受累,在发声时产生不受控制的痉挛,并出现一种通常称为“痉挛性发音障碍”的“紧张-窒息”言语模式。其他患者的外展肌受累,产生“耳语性发音障碍”。罕见患者在呼吸时出现矛盾性声带运动,吸气时内收肌痉挛。在过去5年中,我们使用肉毒杆菌毒素(保妥适)治疗了200多名喉肌张力障碍患者。该组包括内收肌受累的患者(发声性肌张力障碍、喉返神经切断术失败、呼吸性肌张力障碍)和外展肌受累的患者(耳语性肌张力障碍)。患者在24至72小时内获益,持续改善2至9个月,平均4个月。患者功能改善至平均正常功能的90%。具有临床意义的不良反应包括持续性呼吸性发音障碍和轻度饮水呛咳。肉毒杆菌毒素已成为我们治疗喉部肌张力障碍疾病的首选方法。